Open AccessStabilized oral nanostructured lipid carriers of Adefovir Dipivoxil as a potential liver targeting: Estimation of liver function panel and uptake following intravenous injection of radioiodinated indicator
Author(s) -
Shady M. Abd ElHalim,
Ghada A. Abdelbary,
Maha M Amin,
Mohamed Y. Zakaria,
Hesham A. Shamsel-Din,
Ahmed B. Ibrahim
Publication year - 2020
Publication title -
daru
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.645
H-Index - 42
eISSN - 2008-2231
pISSN - 1560-8115
DOI - 10.1007/s40199-020-00355-8
Subject(s) - adefovir , bioavailability , pharmacology , chemistry , lecithin , drug , pharmacokinetics , drug carrier , liver function , oral administration , biochemistry , medicine , hepatitis b virus , immunology , lamivudine , virus
Adefovir dipivoxil (AD), a nucleoside reverse transcriptase inhibitor is effective against Hepatitis B virus. Its poor oral bioavailability leads to frequent administration causing severe adverse effects. Thereby the entrapment of AD within lipid nanoparticulate systems is a way of increasing AD oral bioavailability as a result of improving intestinal permeability with efficient liver-targeted delivery together with higher drug stability during storage.